Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kermanian propolis is a natural resinous substance produced by honeybees in the Kerman province of Iran. Its chemical composition is unique to the geographic region and local flora, typically containing a variety of bioactive compounds such as polyphenols and flavonoids. Research has identified Kermanian propolis as a potential anti-tumor agent, particularly in the context of hematological malignancies. It has been shown to induce apoptosis in acute myeloid leukemia (AML) cell lines, such as NB4, by modulating the expression of key apoptotic regulators. Specifically, it increases the Bax/Bcl-2 ratio, thereby activating the intrinsic mitochondrial pathway of programmed cell death. Additionally, it is being investigated for its synergistic potential when combined with standard chemotherapeutic agents like cytarabine to enhance cytotoxic effects against leukemia cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kermanian propolis.